BioCryst Pharmaceuticals Stock Market Outlook
| BCRX Stock | USD 8.83 -0.20 -2.21% |
This sentiment measure is descriptive rather than personalized advice and should be used with other evidence before acting on it. Around 62% of recent sentiment around BioCryst Pharmaceuticals has leaned defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for BioCryst Pharmaceuticals below neutral at this time.
Investor Comfort Level
PanicConfidence
38 · Alarmed
Elasticity to Hype and News Sentiment
BioCryst Pharmaceuticals news coverage registers mixed at 50%, a data point that gauges whether public narrative is leading or lagging the business reality. That reading becomes more actionable when paired with valuation context and recent technical trend direction.
Given a 90-day horizon, with an above-average risk tolerance, the model output for BioCryst Pharmaceuticals is 'Strong Buy'. Our automated recommendation for BioCryst Pharmaceuticals is built from quantitative evidence and fundamental indicators. The analysis combines quantitative signals with investor-specific risk parameters. The recommendation evaluates return potential against downside risk within defined investment parameters. Complementing automated signals with independent research strengthens the broad analytical foundation.
BioCryst |
Run BioCryst Pharmaceuticals Outlook Model
Our BioCryst outlook engine provides a data-driven supplement to the analyst consensus on BioCryst Pharmaceuticals. Macroaxis has no vested interest in BioCryst Pharmaceuticals or any other instrument analyzed here. Multiple quantitative inputs drive the BioCryst Pharmaceuticals' signal across different market conditions. Combining algorithmic signals with independent analysis supports more informed decisions.
How This Model Works
The recommendation output for BioCryst Pharmaceuticals is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Buy
Market Performance | Balanced | Details | |
Volatility | Stable | Details | |
Current Valuation | Below Model Estimate | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
BioCryst Pharmaceuticals' current outlook reflects mixed signals, where elevated leverage adds balance-sheet risk to the outlook, while contained volatility and intact fundamental quality provide partial offset. The model's 'Strong Buy' signal reflects this balance across quantitative inputs rather than a directional bias. For the selected horizon, BioCryst Pharmaceuticals yields Risk Adjusted Performance of 0.1863, Jensen Alpha of 0.5883, and Total Risk Alpha of 0.5593, which collectively support the constructive outlook.The quantitative analytical reading for BioCryst Pharmaceuticals blends historical performance patterns with current market conditions and the analyst and expert consensus to frame the risk-reward profile. For additional context on this mid-cap stock, review the full set of BioCryst Pharmaceuticals reported fundamentals, including the relationship between the cash per share ttm and market capitalization ttm. BioCryst Pharmaceuticals reports a price to earnings ttm of -7.11 X. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with BioCryst Pharmaceuticals. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
Plotting BioCryst Pharmaceuticals' daily returns in a distribution reveals the day-to-day behavior of BioCryst Pharmaceuticals. It shows how returns are grouped around the average and how often large swings occur. Value At Risk and Upside Potential quantify both the risk and the reward. Value At Risk shows the worst-case boundary and Upside Potential shows the best-case boundary.
| Mean Return | 0.60 | Value At Risk | -3.26 | Potential Upside | 5.01 | Standard Deviation | 3.24 |
Return Density |
| Distribution |
Risk management for BioCryst Pharmaceuticals depends on quantifying the frequency and magnitude of extreme moves. The distribution chart below makes that clear for BioCryst Pharmaceuticals. Portfolio managers weigh the trade-offs across risk-return profiles. Return distribution analysis highlights the frequency and magnitude of extreme price moves in BioCryst Pharmaceuticals.
Key Drivers of Volatility and Market Exposure
Market risk ties BioCryst Pharmaceuticals to macro cycles, whereas company or sector-specific developments represent independent drivers. Volatility metrics help measure this balance. BioCryst Pharmaceuticals reported a Downside Deviation of 2.21, a Mean Deviation of 2.33, and a Semi Deviation of 1.92.
α | Alpha over Dow Jones | 0.59 | |
β | Beta against Dow Jones | 0.44 | |
σ | Overall volatility | 3.24 | |
Ir | Information ratio | 0.18 |
Fundamentals Vs Peers
BioCryst Pharmaceuticals is measured here against stocks with similar revenue scale, margin profile, and capital structure. The comparison below reveals whether BioCryst Pharmaceuticals generates superior or inferior returns relative to similar stocks. Divergence between BioCryst Pharmaceuticals' valuation multiples and its peer group flags either mispricing or a structural difference in quality. Direct comparison with similar stocks converts BioCryst Pharmaceuticals's standalone financial data into an actionable relative signal.
| Better Than Average | Worse Than Average | Compare BioCryst Pharmaceuticals to competition |
Note: Insider Trading [view details]
Market Momentum
With RSI at 52 and beta at 0.437, BioCryst Pharmaceuticals strength signals show whether demand and trading pressure are supporting or weakening the current setup. The business is commonly classified in the Healthcare sector and the Biotechnology industry. Together, these momentum and sensitivity readings help investors judge whether a position adjustment or patience is warranted.
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 8.82 | |||
| Day Typical Price | 8.82 | |||
| Price Action Indicator | -0.09 | |||
| Period Momentum Indicator | -0.20 | |||
| Relative Strength Index | 52.01 |
Recommendation Framework, Assumptions & Editorial Oversight
The model output for BioCryst Pharmaceuticals reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for BioCryst Pharmaceuticals include ROE of -19.25%, market cap of 2.34 billion. 
BioCryst Pharmaceuticals metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.